NASDAQ:IMTX Immatics Q1 2026 Earnings Report $8.37 +0.04 (+0.48%) Closing price 04:00 PM EasternExtended Trading$8.38 +0.01 (+0.12%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Immatics EPS ResultsActual EPS-$0.50Consensus EPS -$0.42Beat/MissMissed by -$0.08One Year Ago EPSN/AImmatics Revenue ResultsActual Revenue$8.81 millionExpected Revenue$9.79 millionBeat/MissMissed by -$981.82 thousandYoY Revenue GrowthN/AImmatics Announcement DetailsQuarterQ1 2026Date5/12/2026TimeBefore Market OpensConference Call DateTuesday, May 12, 2026Conference Call Time7:00AM ETUpcoming EarningsImmatics' Q3 2026 earnings is estimated for Tuesday, November 17, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (6-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K) Immatics Earnings HeadlinesCritical Analysis: MiMedx Group (NASDAQ:MDXG) versus Immatics (NASDAQ:IMTX)September 21, 2026 | americanbankingnews.comImmatics N.V. (NASDAQ:IMTX) Receives $20.60 Consensus PT from BrokeragesSeptember 20, 2026 | americanbankingnews.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.September 25 at 1:00 AM | Banyan Hill Publishing (Ad)Immatics and 4 more stocks see action from activist investorsSeptember 4, 2026 | msn.comImmatics Raises $161 Million in Completed Equity Offering to Advance PRAME Cancer ProgramsAugust 26, 2026 | tipranks.comImmatics N.v Share Price (IMTX.US)August 25, 2026 | lse.co.ukSee More Immatics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Immatics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immatics and other key companies, straight to your email. Email Address About ImmaticsImmatics (NASDAQ:IMTX) is a biopharmaceutical company focused on developing T cell receptor (TCR)-based therapies for cancer. The company aims to identify cancer targets that are presented on the surface of tumor cells and develop treatments that enable T cells to recognize and attack those cells, including targets that may be difficult to address with conventional antibody-based medicines. Immatics’ technology platforms support two primary approaches: TCR-engineered T-cell therapies, known as TCR-T, and TCR-based bispecific molecules designed to direct patients’ T cells toward tumor cells. Its pipeline has included investigational programs targeting cancer-associated antigens such as PRAME, with potential applications across solid tumors and other cancers. These programs remain subject to clinical development and regulatory review. Founded in 2000, Immatics is headquartered in Tübingen, Germany, and operates internationally, serving the global biopharmaceutical market through its research, clinical-development and strategic collaboration activities. The company’s leadership includes Harpreet Singh, Ph.D., who serves as chief executive officer. Immatics’ American depositary shares trade on the Nasdaq Global Select Market under the symbol “IMTX.”View Immatics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Costco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic ProblemSuper Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Space Stocks to Watch as SpaceX Reshapes the Launch MarketOil May Be Stronger Than It Looks—And Diamondback Is on SaleBlackBerry Shifts Gears With Coretura Deal Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
